Trine Schütt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Trine Schütt has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Mette Berendt
Department of Veterinary Clinical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
3 shared publications - Nils Toft
National Veterinary Institute, Technical University of Denmark, Bülowsvej 27, 1870 Frederiksberg C, Denmark
3 shared publications A. Møller
Centre of Functionally Integrative Neuroscience (CFIN), Aarhus University , Aarhus
1 shared publication- Annemarie Thuri Kristensen
Department of Veterinary Clinical and Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
1 shared publication - Henrik Duelund Pedersen
Novo Nordisk A/S , Måløv
1 shared publication Karen Qvortrup
Departments of Anatomy and Physiology, The Royal Veterinary and Agricultural University, Frederiks‐berg, Denmark
1 shared publication
Latest Publications
- Open Access
- 1 November 2015
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 29 (6) , 1569-1577
Cognitive Function, Progression of Age-related Behavioral Changes, Biomarkers, and Survival in Dogs More Than 8 Years Old
Background: Canine cognitive dysfunction (CCD) is an age-dependent neurodegenerative condition dominated by changes in behavioral patterns. Cohort studies investigating cognitive status in dogs are lacking. Objectives: To investigate cognitive function, progression of age-related behavioral changes, survival, and possible biomarkers of CCD in aged dogs. Animals: Fifty-one dogs >8 years old; 21 with no cognitive deficits, 17 with mild cognitive impairments (MCI) and 13 with CCD. Methods: Longitudinal study. Recruitment period of 12 months and an observational period of 24 months including a baseline and 3 planned subsequent assessments. Cognitive status was determined using validated questionnaires. Plasma Aβ-peptides were quantified using commercial ELISA assays and cytokines by a validated immunoassay. Results: Signs characterizing dogs with CCD were aimless wandering, staring into space, avoid getting patted, difficulty finding dropped food and anxiety. Thirty-three percent of dogs with a normal cognitive status progressed to MCI and 22% classified as MCI progressed to CCD during the study period. For 6 dogs diagnosed with CCD, signs of cognitive dysfunction increased with time. A diagnosis of CCD did not affect survival. The level of plasma Aβ42 was significantly increased (P < .05) in the CCD group (92.8 ± 24.0 pg/mL) compared to the MCI (77.0 ± 12.3 pg/mL) and normal group (74.9 ± 10.0 pg/mL), but no significant differences in concentrations of systemic inflammatory markers were detected. Conclusions: Canine cognitive dysfunction is a progressive disorder with an individual variability in the rate of cognitive decline and clinical signs. Plasma Aβ42 seems to be an interesting plasma biomarker of CCD.
- 1 November 2015
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 29 (6) , 1569-1577
Open AccessCognitive Function, Progression of Age-related Behavioral Changes, Biomarkers, and Survival in Dogs More Than 8 Years Old
Background: Canine cognitive dysfunction (CCD) is an age-dependent neurodegenerative condition dominated by changes in behavioral patterns. Cohort studies investigating cognitive status in dogs are lacking. Objectives: To investigate cognitive function, progression of age-related behavioral changes, survival, and possible biomarkers of CCD in aged dogs. Animals: Fifty-one dogs >8 years old; 21 with no cognitive deficits, 17 with mild cognitive impairments (MCI) and 13 with CCD. Methods: Longitudinal study. Recruitment period of 12 months and an observational period of 24 months including a baseline and 3 planned subsequent assessments. Cognitive status was determined using validated questionnaires. Plasma Aβ-peptides were quantified using commercial ELISA assays and cytokines by a validated immunoassay. Results: Signs characterizing dogs with CCD were aimless wandering, staring into space, avoid getting patted, difficulty finding dropped food and anxiety. Thirty-three percent of dogs with a normal cognitive status progressed to MCI and 22% classified as MCI progressed to CCD during the study period. For 6 dogs diagnosed with CCD, signs of cognitive dysfunction increased with time. A diagnosis of CCD did not affect survival. The level of plasma Aβ42 was significantly increased (P < .05) in the CCD group (92.8 ± 24.0 pg/mL) compared to the MCI (77.0 ± 12.3 pg/mL) and normal group (74.9 ± 10.0 pg/mL), but no significant differences in concentrations of systemic inflammatory markers were detected. Conclusions: Canine cognitive dysfunction is a progressive disorder with an individual variability in the rate of cognitive decline and clinical signs. Plasma Aβ42 seems to be an interesting plasma biomarker of CCD.
- 1 November 2015
- Published by Elsevier in Journal of Veterinary Behavior
- Vol. 10 (6) , 452-458
A comparison of 2 screening questionnaires for clinical assessment of canine cognitive dysfunction
- 1 November 2015
- Published by Elsevier in Journal of Veterinary Behavior
- Vol. 10 (6) , 452-458
A comparison of 2 screening questionnaires for clinical assessment of canine cognitive dysfunction
- 1 July 2013
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 27 (4) , 822-829
An Observational Study with Long-Term Follow-Up of Canine Cognitive Dysfunction: Clinical Characteristics, Survival, and Risk Factors
Background: Canine cognitive dysfunction (CCD) is a neurodegenerative condition affecting geriatric dogs and sharing several characteristics with human Alzheimer's disease (AD). CCD manifests as alterations of behavioral patterns and daily routines. Clinical signs are associated with neurodegenerative changes (eg, cortical atrophy and amyloid-beta deposits). Objectives: To investigate clinical characteristics, survival, and risk factors with CCD. Vitamin E was investigated as a potential marker of CCD. Methods: Ninety-four dogs >8 years of age were investigated with a validated CCD questionnaire and allocated to CCD, borderline CCD (b-CCD) and non-CCD groups. The dogs were included in 2008–2009 and followed up in an observational study until follow-up in 2012. Results: Four key clinical signs dominated in dogs with CCD: sleeping during the day and restless at night, decreased interaction, disorientation at home, and anxiety. A number of borderline CCD cases developed into CCD over time indicating that a prodromal stage of CCD may exist. CCD did not influence survival negatively. Small breeds did not show better survival than large breeds (P = .055) and there was no difference between sexes (P = .99). Conclusions and Clinical Importance: A few key questions addressing sleep-wake cycle, interaction, and signs of confusion and anxiety can be used as a clinical marker of CCD. Special attention should be paid to anxiety in dogs with CCD because it may be especially stressful to both dog and owner. Dogs with CCD seem to have a good chance of living a full lifespan if supported by the veterinarian and the owner.
- 1 July 2013
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 27 (4) , 822-829
An Observational Study with Long-Term Follow-Up of Canine Cognitive Dysfunction: Clinical Characteristics, Survival, and Risk Factors
Background: Canine cognitive dysfunction (CCD) is a neurodegenerative condition affecting geriatric dogs and sharing several characteristics with human Alzheimer's disease (AD). CCD manifests as alterations of behavioral patterns and daily routines. Clinical signs are associated with neurodegenerative changes (eg, cortical atrophy and amyloid-beta deposits). Objectives: To investigate clinical characteristics, survival, and risk factors with CCD. Vitamin E was investigated as a potential marker of CCD. Methods: Ninety-four dogs >8 years of age were investigated with a validated CCD questionnaire and allocated to CCD, borderline CCD (b-CCD) and non-CCD groups. The dogs were included in 2008–2009 and followed up in an observational study until follow-up in 2012. Results: Four key clinical signs dominated in dogs with CCD: sleeping during the day and restless at night, decreased interaction, disorientation at home, and anxiety. A number of borderline CCD cases developed into CCD over time indicating that a prodromal stage of CCD may exist. CCD did not influence survival negatively. Small breeds did not show better survival than large breeds (P = .055) and there was no difference between sexes (P = .99). Conclusions and Clinical Importance: A few key questions addressing sleep-wake cycle, interaction, and signs of confusion and anxiety can be used as a clinical marker of CCD. Special attention should be paid to anxiety in dogs with CCD because it may be especially stressful to both dog and owner. Dogs with CCD seem to have a good chance of living a full lifespan if supported by the veterinarian and the owner.
- Open Access
- 1 January 2003
- Published by Wiley in Journal of Veterinary Internal Medicine
- Vol. 17 (2) , 178-184
Decreased Plasma Concentration of Nitric Oxide Metabolites in Dogs with Untreated Mitral Regurgitation
- 1 January 2003
- Published by Wiley in Journal of Veterinary Internal Medicine
- Vol. 17 (2) , 178-184
Open AccessDecreased Plasma Concentration of Nitric Oxide Metabolites in Dogs with Untreated Mitral Regurgitation